1. Arginine Modulates Carbapenem Deactivation by OXA-24/40 in Acinetobacter baumannii
- Author
-
Kayla Dempster, Michael W. Staude, Elizaveta Kovrigina, Sara Braynard, Erin Graney, Jamie VanPelt, Jeffrey W. Peng, Heath A. Rose, Sarah Graney, Shannon Stoffel, and David A. Leonard
- Subjects
Acinetobacter baumannii ,Models, Molecular ,Carbapenem ,Arginine ,Allosteric regulation ,Microbial Sensitivity Tests ,Molecular Dynamics Simulation ,Protein Structure, Secondary ,beta-Lactamases ,Article ,Microbiology ,Bacterial Proteins ,Structural Biology ,Catalytic Domain ,Drug Resistance, Multiple, Bacterial ,polycyclic compounds ,medicine ,Molecular Biology ,biology ,Chemistry ,Hydrolysis ,Doripenem ,Mutagenesis ,Active site ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,Anti-Bacterial Agents ,biology.protein ,bacteria ,Bacteria ,medicine.drug - Abstract
The resistance of Gram-negative bacteria to β-lactam antibiotics stems mainly from β-lactamase proteins that hydrolytically deactivate the β-lactams. Of particular concern are the β-lactamases that can deactivate a class of β-lactams known as carbapenems. Carbapenems are among the few anti-infectives that can treat multi-drug resistant bacterial infections. Revealing the mechanisms of their deactivation by β-lactamases is a necessary step for preserving their therapeutic value. Here, we present NMR investigations of OXA-24/40, a carbapenem-hydrolyzing Class D β-lactamase (CHDL) expressed in the gram-negative pathogen, Acinetobacter baumannii. Using rapid data acquisition methods, we were able to study the “real-time” deactivation of the carbapenem known as doripenem by OXA-24/40. Our results indicate that OXA-24/40 has two deactivation mechanisms: canonical hydrolytic cleavage, and a distinct mechanism that produces a β-lactone product that has weak affinity for the OXA-24/40 active site. The mechanisms issue from distinct active site environments poised either for hydrolysis or β-lactone formation. Mutagenesis reveals that R261, a conserved active site arginine, stabilizes the active site environment enabling β-lactone formation. Our results have implications not only for OXA-24/40, but the larger family of CHDLs now challenging clinical settings on a global scale.
- Published
- 2021